Michelle Kittleson
Overview
Explore the profile of Michelle Kittleson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Maurer M, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei L, et al.
Adv Ther
. 2024 Jun;
41(7):2723-2742.
PMID: 38833142
Introduction: Hereditary transthyretin amyloidosis (ATTRv, also referred to as hATTR; ORPHA 271861) and wild-type ATTR amyloidosis (ATTRwt; ORPHA 330001) are rare, progressive, systemic protein misfolding disorders with heterogeneous clinical presentations....
12.
Warner E, Pritting C, Dutta S, Bierowski M, Ullah W, Brailovsky Y, et al.
Artif Organs
. 2024 May;
48(10):1180-1189.
PMID: 38803277
Background: The Organ Procurement and Transplantation Network (OPTN) implemented modifications in 2018 to the adult heart transplant allocation system to better stratify the most medically urgent transplant candidates. We evaluated...
13.
Lee A, Barforoshi S, Singh A, Shrestha R, Ha J, Kittleson M
JACC Case Rep
. 2024 Mar;
29(6):102255.
PMID: 38549854
Dobutamine is a positive inotropic agent often used in treatment of cardiogenic shock. Although there are well-documented adverse effects, dobutamine-induced myoclonus is a rarely reported phenomenon. Our case offers a...
14.
Jaiswal A, Kittleson M, Pillai A, Baran D, Baker W
J Heart Lung Transplant
. 2024 Jan;
43(5):806-815.
PMID: 38232792
Background: Utilization of heart from older donors is variable across centers with uncertain outcomes of recipients. We sought to utilize a national registry to examine the usage and outcomes of...
15.
Kobashigawa J, VanWagner L, Hall S, Emamaullee J, Entwistle J, Ganger D, et al.
Am J Transplant
. 2023 Dec;
24(3):380-390.
PMID: 38072122
Patients with severe heart disease may have coexisting liver disease from various causes. The incidence of combined heart-liver transplant (CHLT) is increasing as more patients with congenital heart disease survive...
16.
Jordan S, Joung S, Wang M, Tran T, Bravo M, Masoom H, et al.
Transpl Infect Dis
. 2023 Oct;
26(1):e14182.
PMID: 37885435
Background: Tixagevimab-cilgavimab (Tix-Cil) was authorized for prophylaxis against COVID-19 in immunocompromised patients from December 2021 through January 2023. Real-world effectiveness for solid organ transplant (SOT) recipients has been unclear. Methods:...
17.
Dhillon M, Kobashigawa J, Kittleson M, Jain R, Patel N, Singer-Englar T, et al.
Clin Transplant
. 2023 Oct;
38(1):e15165.
PMID: 37837612
Background: The use of bortezomib which is a proteasome inhibitor has been demonstrated to be efficacious in small number of patients as a desensitization strategy in heart transplant. We reviewed...
18.
Coutance G, Kobashigawa J, Kransdorf E, Loupy A, Desire E, Kittleson M, et al.
J Heart Lung Transplant
. 2023 May;
42(10):1464-1468.
PMID: 37182818
Allosensitization represents a major barrier to heart transplantation. We previously reported favorable 1-year outcomes of complement inhibition at transplant in highly sensitized recipients. We now report a longer follow-up. In...
19.
Malas J, Chen Q, Emerson D, Megna D, Catarino P, Czer L, et al.
J Heart Lung Transplant
. 2023 Apr;
42(8):1045-1053.
PMID: 37098375
Background: Given ongoing donor shortages, appropriate patient selection for dual-organ transplantation is critical. We evaluated outcomes of heart retransplant with simultaneous kidney transplant (HRT-KT) vs isolated heart retransplant (HRT) across...
20.
Punnoose L, Siddiqi H, Rosenthal J, Kittleson M, Witteles R, Alexander K
Card Fail Rev
. 2023 Mar;
9:e01.
PMID: 36891177
Disease-modifying therapies in both light chain and transthyretin amyloidosis have improved patient functional status and survival. Conceivably, as heart failure may progress despite amyloid therapies, more patients may be considered...